MX2021003559A - Inhibidores de vap-1. - Google Patents

Inhibidores de vap-1.

Info

Publication number
MX2021003559A
MX2021003559A MX2021003559A MX2021003559A MX2021003559A MX 2021003559 A MX2021003559 A MX 2021003559A MX 2021003559 A MX2021003559 A MX 2021003559A MX 2021003559 A MX2021003559 A MX 2021003559A MX 2021003559 A MX2021003559 A MX 2021003559A
Authority
MX
Mexico
Prior art keywords
vap
inhibitors
modulation
activity
compounds
Prior art date
Application number
MX2021003559A
Other languages
English (en)
Inventor
Mark W Orme
Vladimir A Kuksa
Edison S Zuniga
Russell Stuart Craft
Eduardo Moreno Saveedra
Johannes Wilhelm Georg Meissner
Hartog Jacobus Antonius Joseph Den
Albert Cornelis Dros
Original Assignee
Acucela Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acucela Inc filed Critical Acucela Inc
Publication of MX2021003559A publication Critical patent/MX2021003559A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

En el presente documento se proporcionan compuestos y métodos de uso de los mismos para la modulación de la actividad de VAP-1.
MX2021003559A 2018-09-28 2019-09-27 Inhibidores de vap-1. MX2021003559A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862738924P 2018-09-28 2018-09-28
PCT/US2019/053481 WO2020069330A2 (en) 2018-09-28 2019-09-27 Inhibitors of vap-1

Publications (1)

Publication Number Publication Date
MX2021003559A true MX2021003559A (es) 2021-08-24

Family

ID=69952172

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003559A MX2021003559A (es) 2018-09-28 2019-09-27 Inhibidores de vap-1.

Country Status (11)

Country Link
US (1) US11787791B2 (es)
EP (1) EP3856176A4 (es)
JP (1) JP2022511374A (es)
CN (1) CN113164454A (es)
AU (1) AU2019351122A1 (es)
BR (1) BR112021005903A2 (es)
CA (1) CA3114208A1 (es)
IL (1) IL281939A (es)
MX (1) MX2021003559A (es)
SG (1) SG11202103062UA (es)
WO (1) WO2020069330A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109988106B (zh) * 2017-12-29 2023-03-31 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN109988109B (zh) * 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
JP2022511371A (ja) * 2018-09-28 2022-01-31 アキュセラ インコーポレイテッド Ｖａｐ－１の阻害剤
US11787791B2 (en) 2018-09-28 2023-10-17 Acucela Inc. Inhibitors of VAP-1
DK3860998T3 (da) 2018-10-05 2024-03-25 Annapurna Bio Inc Forbindelser og sammensætninger til behandlinger af tilstande, der er forbundet med APJ-receptoraktivitet
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
BR112021010341A2 (pt) 2018-12-14 2021-08-24 Yuhan Corporation 3,3-difluoroalilaminas ou sais das mesmas e composições farmacêuticas que compreendem as mesmas
TW202128675A (zh) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 作為鈉通道調節劑之經取代四氫呋喃
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
CN114644539B (zh) * 2022-04-01 2023-07-14 安徽农业大学 一种含烯烃的二氟芳氧醚的合成方法及其在农药中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
KR20060135781A (ko) 2004-02-25 2006-12-29 라 졸라 파마슈티칼 컴파니 질병의 치료를 위한 아민 및 아미드
WO2006015263A2 (en) 2004-07-29 2006-02-09 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
WO2009066152A2 (en) 2007-11-21 2009-05-28 Pharmaxis Ltd. Haloallylamine inhibitors of ssao/vap-1 and uses therefor
US20110275684A1 (en) 2009-01-19 2011-11-10 Neurosearch A/S Novel benzotriazole derivatives useful for the treatment of cns disorders
ES2668300T3 (es) * 2012-05-02 2018-05-17 Boehringer Ingelheim International Gmbh Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos
LT3019482T (lt) 2013-02-25 2018-11-26 Aurigene Discovery Technologies Limited Tripakeistieji benzotriazolo dariniai kaip dihidroorotato oksigenazės inhibitoriai
GB201321740D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EA201990951A1 (ru) 2016-10-19 2019-11-29 Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
CN109810041B (zh) * 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109988106B (zh) 2017-12-29 2023-03-31 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
US11787791B2 (en) 2018-09-28 2023-10-17 Acucela Inc. Inhibitors of VAP-1

Also Published As

Publication number Publication date
BR112021005903A2 (pt) 2021-07-27
SG11202103062UA (en) 2021-04-29
IL281939A (en) 2021-05-31
US20210387975A1 (en) 2021-12-16
EP3856176A2 (en) 2021-08-04
WO2020069330A2 (en) 2020-04-02
JP2022511374A (ja) 2022-01-31
WO2020069330A3 (en) 2020-07-23
EP3856176A4 (en) 2022-05-04
AU2019351122A1 (en) 2021-05-20
CN113164454A (zh) 2021-07-23
CA3114208A1 (en) 2020-04-02
US11787791B2 (en) 2023-10-17

Similar Documents

Publication Publication Date Title
MX2021003559A (es) Inhibidores de vap-1.
IL271149A (en) Compounds for modulating s1p1 activity and methods of using them
PH12018501656A1 (en) Methods for using fxr agonists
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
MX2021003731A (es) Inhibidores de vap-1.
MX2022001834A (es) Terapias combinadas de inhibidores de hdac e inhibidores de pd-1.
MX2022013114A (es) Inhibidores de diana de rapamicina en celulas de mamifero de complejo 1 (mtorc1).
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2019001223A (es) Moduladores de receptores de quimioquina y usos de los mismos.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
MX2020007812A (es) Moduladores del receptor de quimiocina y usos de los mismos.
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
MX2021004710A (es) Compuestos polimorficos y usos de los mismos.
MX2020012893A (es) Formulaciones de proteinas.
MX2021016050A (es) Formulaciones transdermicas.
NZ740817A (en) Pcna inhibitors
IL286681A (en) Compounds and methods for modulating ube3a-ats
MX2020004058A (es) Inhibidores de d-aminoacido oxidasa y sus usos terapeuticos.
MX2022006750A (es) Inhibidores de masp-2 y metodos de uso.
MX2022006312A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2020005557A (es) Agonistas de fxr para el tratamiento de enfermedades hepaticas.
MX2020003575A (es) Nuevos derivados de alcoxiamino para tratar dolor y estados relacionados con dolor.
WO2018075598A8 (en) SYNTHESIS OF EZH2 INHIBITORS